Jaguar Health Regains Nasdaq Bid Price Compliance
Jaguar Health, Inc. announced it has regained compliance with Nasdaq's Bid Price Rule, ensuring its continued listing on The Nasdaq Stock Market LLC. While compliance has been achieved, the Nasdaq Hearings Panel will maintain jurisdiction until September 1, 2026, and the company will be under a mandatory one-year monitoring period until May 26, 2027. During this monitoring period, any future non-compliance with the bid price rule will lead to an immediate delisting determination without the usual grace period. The company also highlighted significant revenue growth in Q1 2026, with an 816% increase over Q1 2025 and a 527% increase over Q4 2025, driven by a US out-license agreement.
Key Highlights
- Jaguar Health regained compliance with Nasdaq Listing Rule 5550(a)(2) (Bid Price Rule) on May 26, 2026.
- The Nasdaq Hearings Panel will maintain jurisdiction over the company's listing until September 1, 2026.
- The company is subject to a Mandatory Panel Monitor for one year, until May 26, 2027.
- During the monitoring period, failure to maintain a $1.00 bid price for 30 consecutive days will result in immediate delisting determination without a grace period.
- Q1 2026 net revenue increased 816% compared to Q1 2025.
- Q1 2026 net revenue increased 527% over Q4 2025.
- Company continues to focus on pivotal-stage development of crofelemer for rare intestinal failure indications.
Price Impact
More from JAGX
Jaguar Health Completes Series O Preferred Stock Conversion; 4.86M Common Shares Outstanding
Jaguar Health Converts Series O Preferred Stock to Common
Jaguar Health Explores Strategic Alternatives for Rare Disease Program